# Carl H. June

Source: https://onco.cc/people/carl-june/  
OnCo record `carl-june` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Developed the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer.

## Summary

Carl H. June is the Richard W. Vague Professor in Immunotherapy and Director of the Center for Cellular Immunotherapies at the Abramson Cancer Center, University of Pennsylvania. He is known for developing the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer, leading the CTL019 programme that included Emily Whitehead's treatment in 2012 and culminated in the approval of tisagenlecleucel in 2017. His selected papers report chimeric antigen receptor-modified T cells in chronic lymphoid leukaemia and CAR T cells producing sustained remissions in leukaemia. His centre developed the 4-1BB CAR design now used widely, and he continues to work on gene-modified T cells for leukaemia and lymphoma.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies
- Specialisms: CAR-T cell therapy; Gene-modified T cells; Cellular immunotherapy

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Carl_H._June
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=June%20CH%5BAuthor%5D

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/), [Children's Hospital of Philadelphia](https://onco.cc/institutions/chop/), [Parker Institute for Cancer Immunotherapy](https://onco.cc/institutions/parker-institute/)
- people: [Emily Whitehead](https://onco.cc/people/emily-whitehead/), [Leonard Abramson](https://onco.cc/people/leonard-abramson/), [Sean Parker](https://onco.cc/people/sean-parker/)
- key papers: [ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL](https://onco.cc/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/), [Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL](https://onco.cc/key-papers/paper-maude-ctl019-all-nejm-2014/)

---
JSON: https://onco.cc/api/v1/entities/carl-june.json